menu
More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Ana
More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Ana
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis

To order this 530+ page report, which features160+ figures and 190+ tables, please visit this link

 

The USD 180+ billion (by 2030) financialopportunity associated with subcutaneous biologics, affiliated drug deliverysystems and subcutaneous formulation technology licensing deals, has beenanalyzed across the following segments:

§  Phaseof development

§ Approved

§ Pre-registration & Phase III

§ Phase II & Phase II/III

 

§  Typeof molecule

§ Cell and gene therapies

§ Monoclonal antibodies

§ Proteins

§ Peptides (recombinant)

§ Vaccines

§ Others

 

§  Targettherapeutic area

§ Autoimmune disorders

§ Blood disorders

§ Bone disorders

§ Genetic disorders

§ Metabolic disorders

§ Neurological disorders

§ Oncological disorders

§ Respiratory disorders

§ Others

 

§  Typeof drug delivery system

§  Large volume wearable injectors

§  Autoinjectors

§  Prefilled syringes

§  Needle-free injectors

§  Drug reconstitution systems

 

§  Revenuesfrom licensing deals

§  Upfront payments

§  Milestone payments

 

§  Keygeographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the World

 

TheSubcutaneous Biologics,Technologies and Drug Delivery Systems (3rd Edition), 2020-2030report features the following companies, which weidentified to be key players in this domain:

§  Adocia

§  AjinomotoBio-Pharma Services

§  Arecor

§  Alteogen

§  AscendisPharma

§  AvadelPharmaceuticals

§  Camurus

§  CreativeBioMart

§  CreativeBiolabs

§  DURECT

§  EaglePharmaceuticals

§  HalozymeTherapeutics

§  MedinCell

§  XerisPharmaceuticals

§  SerinaTherapeutics

 

Table of Contents

1.    Preface

 

2.    Executive Summary

 

3.    Introduction

 

4.    Subcutaneous Biologics: CurrentMarket Landscape

 

5.    Case Study: Leading SubcutaneousBiologics

 

6.    Subcutaneous FormulationTechnologies: Current Market Landscape

 

7.    Subcutaneous FormulationTechnology Developers: Company Competitiveness Analysis

 

8.    Subcutaneous FormulationTechnology Developers: Company Profiles

 

9.    Partnerships and Collaborations

 

10.  SubcutaneousDrug Delivery Systems: Current Market Landscape

 

11.  SwotAnalysis

 

12.  MarketForecast and Opportunity Analysis

 

13.  ConcludingRemarks

 

14.  ExecutiveInsights

 

15.  Appendix1:  Tabulated Data

 

16.  Appendix2: List Of Companies And Organization

 

 

To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

Contact Details

Gaurav Chaudhary

+1(415) 800 3415

+44(122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com